Quantcast

Latest diabetic neuropathy Stories

2009-10-30 07:30:00

SAN MATEO, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will hold a conference call on Friday, November 6, 2009 at 9:00 a.m. ET (6:00 a.m. PT) to report results for its third quarter 2009. The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer. To...

2009-10-27 14:36:36

HealthCore study shows Metanx also reduces health plan costs Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress. The results of the HealthCore, Inc. study, funded by Pamlab, L.L.C., which manufactures the medical food...

2009-10-27 01:00:00

PARIS, Oct. 27 /PRNewswire/ -- Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress. The results of the HealthCore, Inc. study, funded by Pamlab, L.L.C., which manufactures the medical food Metanx®,...

2009-10-20 13:00:00

RICHMOND, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of top-line, statistically significant Phase 2 clinical data from its ZFP Therapeutic(TM) program to develop SB-509 as a treatment for diabetic neuropathy (DN) at the Society for Neuroscience Annual Meeting held in Chicago. Top-line data from Sangamo's SB-509-601 Phase 2 clinical trial demonstrated a direct neuroregenerative effect of SB-509 treatment that...

2009-10-01 10:12:00

People who suffer from debilitating neuropathic pain may get more relief and sleep better by combining two commonly-prescribed drugs. A new, federally-funded study by Queen's University researchers has found that taking the drugs together is a more effective treatment than taking either of them individually. When given both an anti-seizure drug (gabapentin) and an antidepressant (nortriptyline), patients suffering from neuropathic pain caused by nerve damage or disease experienced less pain...

2009-09-22 12:17:00

NEW YORK, Sept. 22 /PRNewswire-USNewswire/ -- The Neuropathy Association has announced two awardees for its annual Scientific Research Grants Program. Every year, The Neuropathy Association--the leading national non-profit organization dedicated to finding cures for peripheral neuropathies--awards two scientific research grants, each for $80,000 over a two-year period. This year's grant recipients--Dennis Paul, Ph.D. and co-principal investigator, Harry J. Gould, M.D., Ph.D. of Louisiana...

2009-09-17 15:01:00

SAN MATEO, Calif., Sept. 17 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the UBS Global Life Sciences Conference, to be held September 21 - 23, 2009 in New York City. Mr. DiTonno and Stephen Ghiglieri, Chief Financial Officer, will also be available to respond to...

2009-09-17 10:40:00

DEL MAR, Calif., Sept. 17 /PRNewswire/ -- In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition's impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49...

2009-07-31 01:25:00

TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows. The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities. 1. Development code UF-021 (eye diseases) The item in question is isopropyl...

2009-07-22 07:09:00

DOYLESTOWN, Pa., July 22 /PRNewswire-FirstCall/ -- Quigley Pharma Inc., a wholly-owned subsidiary of The Quigley Corporation (Nasdaq: QGLY) www.quigleyco.com, today announced the results from its Phase IIb double-blind, placebo-controlled, study of topical compound QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. The study was completed with fewer than expected evaluable patients with the final and comprehensive conclusions revealing that (i) the compound is safe and...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.